Unusual high dose of tacrolimus in liver transplant patient, a case report

International Journal of Clinical Pharmacy

Volumn 34, Issue 2, 2012, Pages 269-271

  Provenzani, Alessio ^a   Notarbartolo, Monica ^b   Labbozzetta, Manuela ^b   Poma, Paola ^b   D'Antoni, Adele ^a   Polidori, Piera ^a   Vizzini, Giovanni ^a   D'Alessandro, Natale ^b  

^a MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

ABCB1; CYP3A5; Liver transplant; Pharmacogenomics; Single nucleotide polymorphisms; Tacrolimus; Trough blood levels

Indexed keywords

ALBUMIN; BASILIXIMAB; CREATININE; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAMIPRIL; TACROLIMUS;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; EXON; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HOMOZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY INJURY; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC HYPERTENSION; TREATMENT RESPONSE; WILD TYPE;

ADULT; CYTOCHROME P-450 CYP3A; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HOMOZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84862844607     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9622-6     Document Type: Article

References (10)

1. Macphee I, Fredericks S, Tai T, et al. Tacrolimus pharmacoge-netics. Polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation. 2002;74:1486-9.
2. van Schaik RHN, Van der Heiden IP, Van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch caucasians. Clin Chem. 2002;48:1668-71.
3. Dirks NL, Huth B, Yates CR, Meibohm B. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther. 2004;42:701-18.
4. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glyco-protein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473-8.
5. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among Europeans Americans and Africans Americans. Clin Pharmacol Ther. 2001;70:189-99.
6. Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, Caccamo C, Bertani T, Palazzo U, Polidori P, Gridelli B, D'Alessandro N. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med. 2011;28:1093-102.
7. Bekersky I, Dressler D, Mekki QA. Dose linearity after oral administration of tacrolimus 1-mg capsules at doses of 3, 7, and 10 mg. Clin Ther. 1999;21:2058-64.
8. Wei-Lin W, Jing J, Shu-sen Z, et al. Tacrolimus dose requirements in relation to donor and recipients ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl. 2006;12:775-80.
9. Zhang Y, Benet LZ. The gut as a barrier to drug absorption. Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001;40:159-68.
10. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther. 2007;82(6):711-25.